362 related articles for article (PubMed ID: 23131184)
21. Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3.
Harikrishnan LS; Kamau MG; Wan H; Inghrim JA; Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Lombardo LJ; Poss MA; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Baldwin KF; Lippy J; Nirschl DS; Qiu R; Miller AV; Khan J; Sack JS; Purandare AV
Bioorg Med Chem Lett; 2011 Mar; 21(5):1425-8. PubMed ID: 21282055
[TBL] [Abstract][Full Text] [Related]
22. Triazine as a promising scaffold for its versatile biological behavior.
Singla P; Luxami V; Paul K
Eur J Med Chem; 2015 Sep; 102():39-57. PubMed ID: 26241876
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and Biological Evaluation of Pyrrolo[2,1-f][1,2,4]triazine C-Nucleosides with a Ribose, 2'-Deoxyribose, and 2',3'-Dideoxyribose Sugar Moiety.
Li Q; Lescrinier E; Groaz E; Persoons L; Daelemans D; Herdewijn P; De Jonghe S
ChemMedChem; 2018 Jan; 13(1):97-104. PubMed ID: 29160955
[TBL] [Abstract][Full Text] [Related]
24. Privileged s-triazines: structure and pharmacological applications.
Shah DR; Modh RP; Chikhalia KH
Future Med Chem; 2014 Mar; 6(4):463-77. PubMed ID: 24635525
[TBL] [Abstract][Full Text] [Related]
25. A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications.
Kerru N; Gummidi L; Maddila S; Gangu KK; Jonnalagadda SB
Molecules; 2020 Apr; 25(8):. PubMed ID: 32326131
[TBL] [Abstract][Full Text] [Related]
26. Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.
Sampognaro AJ; Wittman MD; Carboni JM; Chang C; Greer AF; Hurlburt WW; Sack JS; Vyas DM
Bioorg Med Chem Lett; 2010 Sep; 20(17):5027-30. PubMed ID: 20675137
[TBL] [Abstract][Full Text] [Related]
27. 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.
Weinberg LR; Albom MS; Angeles TS; Breslin HJ; Gingrich DE; Huang Z; Lisko JG; Mason JL; Milkiewicz KL; Thieu TV; Underiner TL; Wells GJ; Wells-Knecht KJ; Dorsey BD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7325-30. PubMed ID: 22041060
[TBL] [Abstract][Full Text] [Related]
28. 1,3,5-Triazines: A promising scaffold for anticancer drugs development.
Cascioferro S; Parrino B; Spanò V; Carbone A; Montalbano A; Barraja P; Diana P; Cirrincione G
Eur J Med Chem; 2017 Dec; 142():523-549. PubMed ID: 29046238
[TBL] [Abstract][Full Text] [Related]
29. Development, Potential Anticancer Activity and the Receptor Profile of Different Functionalized 1,3,5-Triazine Derivatives.
Sarhan MO; Motaleb MA; Ibrahim IT; Anwar MM; Zaghary WA
Mini Rev Med Chem; 2018; 18(15):1302-1320. PubMed ID: 28971773
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of Medicinally Privileged Heterocycles through Dielectric Heating.
Bandyopadhyay D; Banik BK
Curr Med Chem; 2017; 24(41):4596-4626. PubMed ID: 28240166
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic evolution of benzimidazole derivatives in the last quinquennial period.
Akhtar W; Khan MF; Verma G; Shaquiquzzaman M; Rizvi MA; Mehdi SH; Akhter M; Alam MM
Eur J Med Chem; 2017 Jan; 126():705-753. PubMed ID: 27951484
[TBL] [Abstract][Full Text] [Related]
32. Studies of chirality effect of 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine on p38alpha by molecular dynamics simulations and free energy calculations.
Chen Q; Cui W; Ji M
J Comput Aided Mol Des; 2009 Oct; 23(10):737-45. PubMed ID: 19672560
[TBL] [Abstract][Full Text] [Related]
33. Structure-activity relationships (SAR) of triazine derivatives: Promising antimicrobial agents.
Liu H; Long S; Rakesh KP; Zha GF
Eur J Med Chem; 2020 Jan; 185():111804. PubMed ID: 31675510
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and antitumor activities of 1,2,3-triazines and their benzo- and heterofused derivatives.
Cascioferro S; Parrino B; Spanò V; Carbone A; Montalbano A; Barraja P; Diana P; Cirrincione G
Eur J Med Chem; 2017 Dec; 142():74-86. PubMed ID: 28615111
[TBL] [Abstract][Full Text] [Related]
35. Imidazothiazole and related heterocyclic systems. Synthesis, chemical and biological properties.
Fascio ML; Errea MI; D'Accorso NB
Eur J Med Chem; 2015 Jan; 90():666-83. PubMed ID: 25499987
[TBL] [Abstract][Full Text] [Related]
36. A Comprehensive Review on Journey of Pyrrole Scaffold Against Multiple Therapeutic Targets.
Mir RH; Mir PA; Mohi-Ud-Din R; Sabreen S; Maqbool M; Shah AJ; Shenmar K; Raza SN; Pottoo FH
Anticancer Agents Med Chem; 2022; 22(19):3291-3303. PubMed ID: 35702764
[TBL] [Abstract][Full Text] [Related]
37. Pyrrolo[2,1-
Matveeva MD; Purgatorio R; Voskressensky LG; Altomare CD
Future Med Chem; 2019 Oct; 11(20):2735-2755. PubMed ID: 31556691
[TBL] [Abstract][Full Text] [Related]
38. Antitumor Activity of s-Triazine Derivatives: A Systematic Review.
Dai Q; Sun Q; Ouyang X; Liu J; Jin L; Liu A; He B; Fan T; Jiang Y
Molecules; 2023 May; 28(11):. PubMed ID: 37298753
[TBL] [Abstract][Full Text] [Related]
39. Preparation and structural analysis of (±)-cis-ethyl 2-sulfanylidenedecahydro-1,6-naphthyridine-6-carboxylate and (±)-trans-ethyl 2-oxooctahydro-1H-pyrrolo[3,2-c]pyridine-5-carboxylate.
Schwehm C; Lewis W; Blake AJ; Kellam B; Stocks MJ
Acta Crystallogr C Struct Chem; 2014 Dec; 70(Pt 12):1161-8. PubMed ID: 25471418
[TBL] [Abstract][Full Text] [Related]
40. Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase.
Schroeder GM; Chen XT; Williams DK; Nirschl DS; Cai ZW; Wei D; Tokarski JS; An Y; Sack J; Chen Z; Huynh T; Vaccaro W; Poss M; Wautlet B; Gullo-Brown J; Kellar K; Manne V; Hunt JT; Wong TW; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2008 Mar; 18(6):1945-51. PubMed ID: 18289854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
